Zacks Small Cap Issues Optimistic Forecast for HURA Earnings

TuHURA Biosciences, Inc. (NASDAQ:HURA) – Equities research analysts at Zacks Small Cap increased their FY2025 earnings per share estimates for TuHURA Biosciences in a research note issued to investors on Monday, November 17th. Zacks Small Cap analyst J. Vandermosten now forecasts that the company will earn ($0.66) per share for the year, up from their prior estimate of ($0.68).

A number of other research firms have also recently issued reports on HURA. Maxim Group dropped their price target on shares of TuHURA Biosciences from $15.00 to $8.00 and set a “buy” rating on the stock in a research note on Friday, November 14th. Weiss Ratings reissued a “sell (e+)” rating on shares of TuHURA Biosciences in a research note on Wednesday, October 8th. Finally, Wall Street Zen upgraded shares of TuHURA Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, September 20th. Two investment analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, TuHURA Biosciences presently has an average rating of “Buy” and a consensus price target of $10.33.

TuHURA Biosciences Stock Down 9.4%

Shares of TuHURA Biosciences stock opened at $1.59 on Thursday. TuHURA Biosciences has a twelve month low of $1.56 and a twelve month high of $7.20. The business has a 50-day moving average price of $2.39 and a 200 day moving average price of $2.68. The firm has a market cap of $81.24 million and a PE ratio of -0.92.

TuHURA Biosciences (NASDAQ:HURA) last issued its earnings results on Friday, November 14th. The company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.01.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Virtu Financial LLC acquired a new stake in shares of TuHURA Biosciences in the third quarter valued at approximately $26,000. JPMorgan Chase & Co. acquired a new position in TuHURA Biosciences during the second quarter worth $27,000. Intech Investment Management LLC purchased a new stake in TuHURA Biosciences in the 2nd quarter valued at $29,000. Invesco Ltd. acquired a new stake in shares of TuHURA Biosciences in the 2nd quarter worth $30,000. Finally, Merck & Co. Inc. purchased a new position in shares of TuHURA Biosciences during the 2nd quarter worth $31,000. 0.62% of the stock is currently owned by institutional investors and hedge funds.

TuHURA Biosciences Company Profile

TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.